Financial Performance - Operating revenues for the three months ended September 30, 2025, were $363 million, a 3% increase from $354 million in the same period of 2024[97]. - The net loss for the three months ended September 30, 2025, was $11 million, compared to a net income of $32 million in the same period of 2024, marking a 134% decline[97]. - Operating revenues for the nine months ended September 30, 2025, decreased by $21 million, or 2%, to $1,075 million compared to $1,096 million in the same period of 2024[130]. - Contract revenues increased by $11 million, or 1%, to $816 million for the nine months ended September 30, 2025, driven by higher average contractual dayrates[131][135]. Contract and Backlog Information - As of September 30, 2025, the total contract backlog was $2,511 million, down from $3,180 million as of December 31, 2024, representing a decrease of approximately 21%[87]. - Contract revenues for the three months ended September 30, 2025, included $280 million from drilling contracts, an increase of $17 million from $263 million in Q3 2024[99]. - The contract backlog is expected to be realized over the following periods: $335 million in 2025, $1,013 million in 2026, $707 million in 2027, and $456 million thereafter[88]. Operational Metrics - The average contractual dayrate increased to $330 thousand in Q3 2025 from $304 thousand in Q3 2024, contributing to a $22 million increase in contract revenues[105]. - Economic utilization for rigs on contract was 91% for Q3 2025, down from 95% in Q3 2024, resulting in an $11 million decrease in contract revenues[108]. - The average Brent oil price was $70 per barrel for the nine months ended September 30, 2025, down from $80 per barrel in 2024, reflecting downward pressure on prices due to increased production and slower demand growth[90][92]. Expenses and Costs - Total operating expenses increased by $30 million, or 10%, to $337 million for the three months ended September 30, 2025, compared to $307 million in the same period of 2024[116]. - Vessel and rig operating expenses rose by $19 million, or 11%, to $191 million for the three months ended September 30, 2025, primarily due to increased activity in Brazil[116][118]. - Depreciation and amortization increased by $16 million, or 38%, to $58 million for the three months ended September 30, 2025, mainly due to capital projects related to the West Auriga and West Polaris[116][119]. - Total operating expenses for the nine months ended September 30, 2025, increased by $125 million, or 14%, to $1,025 million compared to $900 million in the same period of 2024[144]. - Management contract expenses rose by $63 million, or 51%, to $187 million for the nine months ended September 30, 2025, primarily due to higher management fees[144]. Debt and Liquidity - As of September 30, 2025, available liquidity was $587 million, consisting of $402 million in unrestricted cash and $185 million in available borrowings[169]. - Total debt as of September 30, 2025, was $625 million, including a $575 million secured bond and a $50 million unsecured senior convertible bond[177]. - The Company entered into a $225 million, 5-year Senior Secured Revolving Credit Agreement, secured by first priority liens on substantially all of its rigs and related assets[178]. - As of September 30, 2025, the available borrowings under the Revolving Credit Facility were reduced to $185 million due to a NOK403 million guarantee issued[179]. Compliance and Financial Covenants - The Credit Agreement requires an Interest Coverage Ratio of not less than 2.50 to 1.00 and a Consolidated Total Net Leverage Ratio of not greater than 3.00 to 1.00 as of the last day of each fiscal quarter[187]. - As of September 30, 2025, the Company was in compliance with all financial covenants outlined in the Credit Agreement[183]. Market Outlook - The company anticipates a market recovery in 2027, despite a projected decrease in utilization and increased competition in 2025[93]. Accounting and Risk Management - The Company has made critical accounting estimates that may affect reported amounts of assets, liabilities, revenues, and expenses[184]. - The Company is exposed to market risks, including foreign exchange risk and interest rate risk, and employs strategies to mitigate these risks[186]. - There have been no material changes to the judgments, assumptions, and estimates upon which the Company's critical accounting policies are based as of September 30, 2025[185].

Financial Performance - MetaVia reported a net loss of $3.4 million, or $0.14 per share, for Q3 2025, compared to a net loss of $5.7 million, or $0.55 per share, in Q3 2024[10] - The net loss for the three months ended September 30, 2025, was $3,377 million, compared to a net loss of $5,652 million for the same period in 2024, indicating an improvement of about 40.2%[19] - Loss per share improved from $(0.55) in Q3 2024 to $(0.14) in Q3 2025, reflecting a significant reduction in losses per share[19] - The company reported a loss before income taxes of $3,377 million for Q3 2025, compared to a loss of $5,652 million in Q3 2024, showing a reduction of about 40.2%[19] Expenses - Research and Development (R&D) expenses decreased to approximately $1.9 million in Q3 2025 from $4.5 million in Q3 2024, a reduction of about 58%[7] - Total operating expenses for Q3 2025 were approximately $3.5 million, down from $6.3 million in Q3 2024, reflecting a decrease of approximately 44%[10] - R&D expenses for the nine months ended September 30, 2025, were approximately $6.6 million, compared to $17.5 million for the same period in 2024, a decrease of about 62%[7] - General and Administrative (G&A) expenses for Q3 2025 were approximately $1.6 million, slightly down from $1.7 million in Q3 2024[10] - General and administrative expenses decreased from $1,742 million in Q3 2024 to $1,561 million in Q3 2025, a reduction of approximately 10.4%[19] Income and Assets - Total other income for Q3 2025 was approximately $0.1 million, down from $0.6 million in Q3 2024, primarily due to lower interest income[10] - Other income for the three months ended September 30, 2025, was $98 million, down from $607 million in Q3 2024, a decrease of approximately 83.8%[19] - Total assets decreased from $16,260 million as of December 31, 2024, to $14,765 million as of September 30, 2025, representing a decline of approximately 9.2%[18] - Total stockholders' equity decreased from $7,931 million as of December 31, 2024, to $6,331 million as of September 30, 2025, a decline of approximately 20.2%[18] Shareholder Information - The weighted average shares of common stock increased from 10,214,087 in Q3 2024 to 24,415,876 in Q3 2025, indicating a significant increase in shares outstanding[19] Clinical Trials and Future Plans - The Phase 1 clinical trial for DA-1726 showed a mean body-weight reduction of up to 6.3% and waist circumference reduction of up to 3.9 inches after four weeks of treatment[3] - The company is preparing for an end-of-Phase 2 meeting with the FDA for vanoglipel (DA-1241) in the first half of 2026[8] - The company expects to report results from the 8-week, 48 mg cohort of the Phase 1 study by year-end 2025[8]

Financial Performance - Revenue for Q3 2025 was $699 million, a 13% decrease year-over-year and a 4% decrease quarter-over-quarter[3]. - Net loss attributable to Tronox was $99 million, or a loss of $0.63 per diluted share, compared to a net loss of $25 million, or a loss of $0.16 per diluted share in Q3 2024[12]. - Adjusted EBITDA was $74 million, representing a 48% decrease year-over-year, with an adjusted EBITDA margin of 10.6%[13]. - Net sales for Q3 2025 were $699 million, a decrease of 13.1% compared to $804 million in Q3 2024[28]. - Gross profit for Q3 2025 was $52 million, down from $128 million in Q3 2024, reflecting a gross margin of 7.4% compared to 15.9%[28]. - Adjusted net loss attributable to Tronox Holdings plc for Q3 2025 was $72 million, compared to $21 million in Q3 2024[29]. - Net loss for the nine months ended September 30, 2025, was $296 million, compared to a net loss of $24 million for the same period in 2024[36]. - Adjusted EBITDA for the nine months ended September 30, 2025, was $279 million, down from $435 million in 2024, representing a decrease of approximately 36%[37]. - Net sales for the three months ended September 30, 2025, were $699 million, compared to $804 million in 2024, reflecting a decline of about 13%[37]. - Adjusted EBITDA as a percentage of net sales for the three months ended September 30, 2025, was 10.6%, down from 17.8% in 2024[37]. Revenue Breakdown - TiO2 revenue was $550 million, down 11% year-over-year, driven by an 8% decline in volumes and a 5% decline in average selling prices[9]. - Zircon revenue decreased 20% to $59 million, impacted by a 16% decrease in average selling prices and a 4% decline in sales volumes[10]. Cash Flow and Liquidity - Free cash flow for Q3 2025 was a use of $137 million, with expectations for positive free cash flow in Q4 2025 and 2026[17][19]. - Free cash flow for the nine months ended September 30, 2025, was $(334) million, compared to $(197) million for the six months ended June 30, 2025[43]. - Cash provided by financing activities for the nine months ended September 30, 2025, was $345 million, contrasting with cash used in financing activities of $(97) million in 2024[36]. - Tronox raised $400 million in senior secured notes, increasing available liquidity to $664 million[16]. Capital Expenditures - Capital expenditures for the quarter were $80 million, focusing on key capital projects to sustain vertical integration[17]. - Capital expenditures for Q3 2025 were $80 million, down from $101 million in Q3 2024[28]. - Capital expenditures for the nine months ended September 30, 2025, were $273 million, compared to $253 million in 2024[36]. Debt and Assets - Long-term debt increased to $3,136 million as of September 30, 2025, compared to $2,759 million at the end of 2024[34]. - Total assets as of September 30, 2025, were $6,303 million, an increase from $6,038 million as of December 31, 2024[34]. - Net debt to trailing-twelve month Adjusted EBITDA ratio increased to 7.5x as of September 30, 2025, compared to 4.8x at the end of 2024[37]. Strategic Initiatives - The company is advancing its rare earth strategy, taking a 5% equity interest in Lion Rock Minerals to support resource development[18]. - The company reported a restructuring charge of $153 million for the nine months ended September 30, 2025, with no such charges reported in 2024[36]. - Tronox Holdings plc's restructuring and other charges amounted to $25 million in Q3 2025, with no such charges reported in Q3 2024[28].

Financial Performance - For the third quarter ended September 30, 2025, net investment income was $0.74 per share, and earnings per share were $0.69[5] - Total investment income for the quarter was $78.7 million, up from $52.2 million in the previous quarter, driven by higher interest income and transaction fees[7] - Net investment income after taxes for the three months ended September 30, 2025, was $38.57 million, compared to $21.62 million for the same period in 2024, representing an increase of 78.5%[24] - Total investment income for the three months ended September 30, 2025, was $78.71 million, a 31.9% increase from $59.63 million in the prior year[24] - Net realized losses on non-controlled, non-affiliated investments for the three months ended September 30, 2025, were $9.61 million, compared to gains of $3.94 million in the same period last year[24] Asset and Investment Overview - The company had total investments at fair value of $1.74 billion across 91 portfolio companies, with 80% in senior secured first lien investments[5] - Total investments at fair value amounted to $1.84 billion, up from $1.82 billion in the previous quarter[22] - Investments on non-accrual status increased to 1.75% of the total investment portfolio at fair value, up from 1.37% as of June 30, 2025[11] - The net asset value per share increased to $14.86, reflecting a 2.5% increase from $14.50 as of June 30, 2025, primarily due to out-earning distributions by $0.38 per share[5] - The net asset value per share of common stock increased to $14.86 at the end of the period, up from $14.50[22] Debt and Liabilities - The net debt-to-equity ratio improved to 1.28x from 1.39x as of June 30, 2025, with total debt outstanding at $1.09 billion[5] - Total liabilities decreased to $1.11 billion from $1.12 billion in the previous quarter[22] Shareholder Actions - The company repurchased 330,324 shares at an average price of $9.86 per share, totaling $3.3 million during the quarter[5] - Management fees for the three months ended September 30, 2025, were $6.53 million, slightly down from $6.85 million in the prior year[24] - The weighted average shares of common stock outstanding were 52,065,707 for the three months ended September 30, 2025[24] Operational Metrics - Operating expenses for the quarter were $40.1 million, an increase from $35.3 million in the previous quarter, primarily due to higher advisory fees[8] - The weighted average interest coverage ratio was 1.94x, slightly improved from 1.93x in the previous quarter[11] - Total assets as of September 30, 2025, were approximately $1.9 billion, reflecting a slight increase from $1.88 billion as of June 30, 2025[25] Future Outlook - The company will shift to monthly base distributions starting January 2026, with a fourth quarter 2025 distribution declared at $0.36 per share[2] - CION Investment Corporation focuses primarily on senior secured loans to U.S. middle-market companies, aiming to generate current income and capital appreciation[25]

EXHIBIT 99.1 Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos"), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the third quarter 2025. "Our Phase 2 B-SUPREME study of pevifoscorvir sodium (pevy) i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2025 Greystone Housing Impact Investors LP (Exact name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation) Delaware 001-41564 47-0810385 (Commission File Number) (IRS Employer Identification No.) 14301 FNB Parkway, Suite 211 Omaha, Nebraska 6815 ...

Financial Performance - Total Bookings increased by $32.6 million, or 14%, for the three months ended September 30, 2025, compared to the same period in 2024, driven primarily by growth in Active CLEAR+ Members and price increases [158]. - Revenue for the three months ended September 30, 2025, was $229,193,000, an increase from $198,424,000 in the same period of 2024 [176]. - Revenue for the three months ended September 30, 2025, increased by $30.8 million, or 16%, to $229.2 million compared to $198.4 million in 2024, driven by a 7% increase in CLEAR+ Members and price increases [192]. - For the nine months ended September 30, 2025, revenue rose by $95.8 million, or 17%, totaling $660.0 million, attributed to the same factors as the quarterly results [194]. - Adjusted EBITDA for the three months ended September 30, 2025, was $70,063,000, compared to $48,645,000 in 2024, reflecting strong operational performance [176]. - Operating income for the three months ended September 30, 2025, was $52.6 million, a 50% increase from $35.1 million in 2024 [192]. - Net income for the three months ended September 30, 2025, was $45.1 million, up 19% from $38.0 million in 2024 [192]. - Free Cash Flow for the nine months ended September 30, 2025, was $155,714,000, compared to $149,806,000 in 2024, indicating positive cash generation [177]. Membership and Engagement - Total Cumulative Enrollments reached 35,751 thousand as of September 30, 2025, representing a 35% increase from 26,453 thousand in 2024, attributed to CLEAR1 and CLEAR+ Member enrollments [161]. - Total Cumulative Platform Uses increased by 59,916 thousand, or 27%, from 220,413 thousand in 2024 to 280,329 thousand in 2025, indicating higher engagement levels among Members [163]. - Active CLEAR+ Members rose by 7% to 7,683 as of September 30, 2025, up from 7,150 in 2024, driven by new members from airports and digital channels [166]. - Annual CLEAR+ Gross Dollar Retention decreased by 2.1% to 86.9% as of September 30, 2025, down from 89.0% in 2024, primarily due to lower pricing increases [168]. - Annual CLEAR+ Member Usage declined by 1% to 7.0x as of September 30, 2025, from 7.1x in 2024, attributed to lower utilization among both new and existing members [170]. Operational Efficiency - The company relies on multiple channels to attract new CLEAR+ Members, including in-airport engagement and digital channels, with strategic partnerships with airlines and American Express to promote services [140]. - The ability to retain existing CLEAR+ Members is crucial, with frequency and recency of usage being key indicators of retention [143]. - The business model is characterized by efficient Member acquisition and high retention rates, but increasing market penetration may raise acquisition costs and affect retention [148]. - Operating expenses include costs related to revenue share fees, direct salaries, and general administrative expenses, which are essential for maintaining service quality and operational efficiency [181][186]. Research and Development - Research and development expenses are focused on developing new products and improving existing services, with costs primarily related to employee expenses and contractor fees [183]. - Research and development expenses increased by $0.6 million, or 3%, for the three months ended September 30, 2025, primarily due to increased employee compensation costs [199]. Cash Flow and Investments - As of September 30, 2025, the company had cash and cash equivalents of $75.8 million and marketable securities of $454.9 million [212]. - Net cash provided by operating activities was $174.0 million for the nine months ended September 30, 2025, an increase of $15.0 million compared to $159.1 million in 2024 [230][231]. - Net cash provided by investing activities decreased by $75.0 million to $73.0 million for the nine months ended September 30, 2025, primarily due to a decrease in net sales of marketable securities [232]. - Net cash used in financing activities was $238.9 million for the nine months ended September 30, 2025, a decrease of $94.3 million compared to $333.2 million in 2024 [233]. - The company repurchased 5,294,598 shares for $126.3 million during the nine months ended September 30, 2025, with $126.5 million remaining available under the repurchase authorization [214]. Market Risks - The company is subject to various macroeconomic factors that could impact travel levels and consumer spending, which are beyond its control [149]. - The company is exposed to market risk related to interest rate changes, with a hypothetical 100 basis points increase or decrease potentially resulting in an unrealized loss or gain of approximately $3.1 million in the fair value of "available for sale" investments [243]. - Foreign currency transaction and translation risk was insignificant for the three and nine months ended September 30, 2025, as the majority of business is transacted in U.S. dollars [244]. Tax and Other Expenses - Income tax expense increased by $11.0 million (231%) for the three months ended September 30, 2025, and by $20.5 million (287%) for the nine months ended September 30, 2025, primarily due to the realization of U.S. deferred tax expense [210][211]. - General and administrative expenses rose by $4.9 million, or 9%, for the three months ended September 30, 2025, mainly due to higher credit card fees and employee compensation costs [204]. - Sales and marketing expenses increased by $1.3 million, or 11%, for the three months ended September 30, 2025, driven by higher employee compensation and commissions [202]. - Cost of revenue share fee increased by $3.1 million, or 11%, for the three months ended September 30, 2025, primarily due to a 16% increase in fixed airport fees [195].

Revenue Performance - Revenue for Q3 2025 was $59.2 million, an increase of $7 million from Q2 2025, driven by orders from India Oil Marketing Companies and stronger ethanol prices[2]. - Total revenues for the first nine months of 2025 were $154.3 million, down from $220.6 million in the same period of 2024, primarily due to reductions in biodiesel contracts in India[8]. Profit and Loss - Gross loss for Q3 2025 was $58 thousand, compared to a gross profit of $3.9 million in Q3 2024[5]. - Net loss for Q3 2025 was $23.7 million, compared to a net loss of $17.9 million in Q3 2024[7]. - Operating loss for the first nine months of 2025 was $34.7 million, compared to $26.9 million for the same period in 2024[9]. - Net loss for the three months ended September 30, 2025, was $23,747 thousand, compared to a net loss of $17,935 thousand for the same period in 2024, representing an increase in loss of 32.5%[23]. - Adjusted EBITDA for the nine months ended September 30, 2025, was $(21,469) thousand, compared to $(9,197) thousand for the same period in 2024, indicating a worsening performance[23]. Cash and Assets - Cash increased to $5.6 million at the end of Q3 2025, up from $900 thousand at the end of 2024, supporting project execution in India[7]. - Total current assets decreased from $44,696 million in December 2024 to $15,554 million in September 2025, a decline of approximately 65.2%[21]. - Total current liabilities surged from $143,968 million in December 2024 to $343,365 million in September 2025, an increase of approximately 138%[21]. - The total stockholders' deficit increased from $(263,928) million in December 2024 to $(304,852) million in September 2025, reflecting a deterioration of approximately 15.5%[21]. Production and Sales - The Dairy Renewable Natural Gas segment produced 114,000 MMBtu from twelve operating digesters, generating $4 million in revenue[4]. - Ethanol gallons sold decreased from 15.5 million in Q3 2024 to 14.7 million in Q3 2025, a decline of 5.2%[25]. - Renewable Natural Gas MMBtu sold increased from 86.0 thousand in Q3 2024 to 114.0 thousand in Q3 2025, an increase of 32.6%[25]. - RINs sold increased from 935.3 thousand in Q3 2024 to 1,020.4 thousand in Q3 2025, an increase of 9.1%[25]. Costs and Pricing - Average sales price per gallon of ethanol increased from $2.12 in Q3 2024 to $2.13 in Q3 2025, a slight increase of 0.5%[25]. - The average delivered cost per bushel of corn decreased from $6.07 in Q3 2024 to $5.95 in Q3 2025, a reduction of 1.97%[25]. Future Plans - Aemetis plans to sell $20 million of Section 45Z and Section 48 tax credits following the completion of a multi-dairy biogas digester in September 2025[2]. - Aemetis is developing a sustainable aviation fuel and renewable diesel fuel biorefinery in California to produce low carbon intensity renewable jet and diesel fuel[12]. Interest Expense - Interest expense for the first nine months of 2025 was $39 million, up from $34 million in the same period of 2024[10].

Sales Performance - For the three months ended September 30, 2025, net sales decreased by 43.7% to $53.0 million from $94.1 million in the same period of 2024[128]. - Direct-to-consumer net sales fell by 34.8% to $42.0 million, while retail net sales dropped by 62.9% to $11.0 million for the same three-month period[145]. - For the nine months ended September 30, 2025, net sales decreased by 28.4% to $222.5 million compared to $311.0 million in the prior year[128]. - Solo Stove net sales decreased by $28,585 (48.1%) to $30,792 for the three months ended September 30, 2025, down from $59,377 in 2024[158]. - Direct-to-consumer net sales for Solo Stove dropped by $13,204 (35.7%) to $23,787 for the three months ended September 30, 2025, compared to $36,991 in 2024[158]. - Chubbies net sales decreased by $3,127 (16.0%) to $16,478 for the three months ended September 30, 2025, down from $19,605 in 2024[163]. - International sales accounted for 7.3% of consolidated net sales for the nine months ended September 30, 2025, compared to 7.5% for the same period in 2024[200]. Profitability and Expenses - Gross profit for the three months ended September 30, 2025, was $31.8 million, a decline of 19.0% from $39.3 million in 2024, with a gross margin of 60.0%[147]. - Operating expenses decreased by $106,582 (68.9%) to $48,023 for the three months ended September 30, 2025, compared to $154,605 in the same period of 2024[151]. - Selling, general and administrative (SG&A) expenses fell by $21,624 (35.4%) to $39,495 for the three months ended September 30, 2025, down from $61,119 in 2024[151]. - Income tax benefit for the three months ended September 30, 2025 was $(552), a decrease of $6,345 (92.0%) compared to $(6,897) in 2024[157]. - Restructuring, contract termination, and impairment charges decreased by $81,678 (97.7%) to $1,940 for the three months ended September 30, 2025, compared to $83,618 in 2024[151]. - Segment operating expenses for the three months ended September 30, 2025, decreased to $11,117,000, a reduction of $1,369,000 or 11.0% compared to $12,486,000 in 2024[169]. - Marketing expenses for the nine months ended September 30, 2025, were $10,453,000, down $2,472,000 or 19.1% from $12,925,000 in 2024[169]. Cost Management and Initiatives - The company implemented cost-saving initiatives in 2025, including a reduction in force costing $914,000 and closure of distribution centers costing $976,000[138]. - The company engaged strategic consulting firms to assist in operational improvements and cost-saving initiatives throughout 2025[136]. - The restructuring activities in 2024 included the closure of distribution centers and termination of underperforming marketing agreements, with cash outlays totaling $9.0 million for marketing terminations[140]. - The company anticipates that macroeconomic factors, including high inflation and interest rates, may further reduce net sales and negatively impact gross margin and cash flows[134]. - The company strategically attempts to mitigate unfavorable impacts from commodity cost changes through collaboration with suppliers and alternative sourcing options[198]. Financial Position and Cash Flow - Cash flows from operating activities for the nine months ended September 30, 2025, were $(53,019,000), an increase in cash usage of $50,549,000 or 2046.5% compared to $(2,470,000) in 2024[184]. - The company had cash and cash equivalents of $16,334,000 and availability under the 2025 Revolving Credit Facility of $60,608,000 as of September 30, 2025[173]. - The 2025 Refinancing Amendment resulted in a decrease in outstanding debt and extended maturities, providing financial flexibility for the company[176]. - The company is required to maintain a minimum Credit Agreement Adjusted EBITDA of $25 million for the twelve months ended December 31, 2025[173]. - Cash provided by financing activities increased by $59,963,000 or 880.3% to $66,775,000 for the nine months ended September 30, 2025, primarily due to net debt activity[184]. - The company settled a $5.4 million obligation to a former vendor for $4.0 million during the nine months ended September 30, 2025[188]. - The company must comply with various financial covenants, including a maximum Total Leverage Ratio and minimum liquidity requirements starting from July 31, 2026[183]. - As of September 30, 2025, the company had indebtedness of $247.1 million with an annualized interest rate of 8.38% under its 2025 Term Loan[195]. - A 100 bps increase in SOFR would increase the company's interest expense by approximately $2.5 million in any given year[195]. Market and Economic Factors - The company expects inventory and costs of goods sold to increase on a per-unit basis due to ongoing tariffs, despite proposed tariff reductions scheduled for November 10, 2025[130]. - Inflationary factors may adversely affect the company's operating results, although no material impact has been observed to date[196]. - The primary cost exposures for the company are with stainless steel and aluminum, which are readily available from multiple vendors[198]. - The company does not currently hedge commodity price risk and may increase product prices to offset cost increases[198]. - The company has not experienced a material impact from foreign currency fluctuations on its net sales[200]. - A 100 bps unfavorable change in foreign currency exchange rates would increase operating expenses and decrease net sales by $0.1 million for the nine months ended September 30, 2025[200].

Exhibit 99.1 Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update Woburn, MA, November 6, 2025 – Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal second quarter ended September 30, 2025 and provided a business update. The Company announced on October 20, 2025, that the U.S. Food and Drug Administration (FDA) has accepted the BLA r ...